Business Standard

Launches, base biz expansion tonic for Dr Reddy's double-digit growth

While the company's bottom line grew 10.5% annually over the 2016-17 through 2021-22 (FY22) period, it is expected to register thrice that growth rate over next two years, observes ICICI Securities

Dr Reddy's
Premium

Growth outlook for Dr Reddy’s will hinge on product pipeline and upcoming launches.

Ram Prasad Sahu
A strong launch pipeline for 2022-23 (FY23), market-share gains, and cost-control efforts are expected to drive strong revenue and earnings growth over the next two years for the country’s fourth-largest pharmaceutical (pharma) company by market capitalisation (m-cap), Dr Reddy’s Laboratories.

While the company’s bottom line grew 10.5 per cent annually over the 2016-17 through 2021-22 (FY22) period, it is expected to register thrice that growth rate over the next two years, observes ICICI Securities. 

The January-March quarter (fourth quarter, or Q4) performance in FY22 and growth in the current financial year (FY23) are the near-term triggers. Double-digit price erosion notwithstanding,

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 22 2022 | 9:46 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com